🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Linda S. Ahn

Linda S. Ahn

Memorial Sloan Kettering Cancer Center

ORCID: 0000-0001-9347-5854

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers”.

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3060

N/A

0.668DataRank · unranked

12 citations

Rachel K. Kim, Linda S. Ahn, Andrew J. Plodkowski, Ai Ni, Mark T.A. Donoghue +10 more

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100256

N/A

0.396DataRank · unranked

13 citations

Eusebio Manchado, Matthew J. Bott, Linda S. Ahn, Yosef Y. Tobi, Andy Ai Ni +14 more

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.10.012

N/A

0.208DataRank · unranked

3 citations

Jake June-Koo Lee, Noura J. Choudhury, Angela B. Hui, Mark Jeng, Jennifer Zheng +20 more

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3484

N/A

0.165DataRank · unranked

2 citations

Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal +9 more

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.09.225

N/A

0DataRank · unranked

37 citations

Pang‐Dian Fan, Besnik Qeriqi, Azadeh Namakydoust, Bobby Daly, Linda S. Ahn +9 more

Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas

Nature Communications(2022)10.1038/s41467-022-33719-6

N/A

0DataRank · unranked

19 citations

Jia Luo, Ni Ai, Rachel Kim, Linda S. Ahn, Anup Biswas +10 more